Delving into the Latest Updates on Anthra Pharmaceuticals, Inc. with Synapse

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known whether AD 32 is more effective with or without BCG after surgery for superficial bladder cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of AD 32 with or without BCG after surgery in treating patients who have newly diagnosed or recurrent superficial bladder cancer.

开始日期1998-11-01

申办/合作机构

Anthra Pharmaceuticals, Inc.

NCT00003725 / Unknown status临床3期

Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors

RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer and may have fewer side effects and improve recovery. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether transurethral resection plus AD 32 is more effective than transurethral resection alone for bladder cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of transurethral resection surgery followed by AD 32 with that of transurethral resection alone in treating patients who have newly diagnosed or recurrent bladder cancer.

开始日期1996-12-01

申办/合作机构

Anthra Pharmaceuticals, Inc.

100 项与 Anthra Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Anthra Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 Anthra Pharmaceuticals, Inc. 相关的文献（医药）

1998-04-08·European journal of medical research

The early cardiovascular toll of cigarette smoking in dyslipidaemic patients in the United Kingdom.

Article

作者: Winder, A ; Butowski, P

Relationships between early cardiovascular risk at mean follow-up 1. 8 years and cigarette smoking status were investigated through analysis of data from participating clinics entered from 1981-1994 in the UK-Lipid Clinics Programme computerised database. Lipid profiles and new cardiovascular events were recorded for 3601 male, 4883 female human non-smokers mean age 44.7 and 53.1 years, 3077 male, 2275 female current smokers age 46.3 and 50.3 years and 7210 male, 4559 female age 49.2 and 53.3 years ever-smokers. Levels of triglycerides and total cholesterol increased across the gradient never/ex/current smoker, with a reverse gradient for HDL-cholesterol. Never-smokers were slightly lighter than other groups and males were younger, differences insufficient to explain the lipid variation. Minor differences in blood pressure between groups did not show this gradient and the development of new hypertension was not consistently related to smoking habits. In contrast the expression of newly-recorded cardiovascular disease was greater and in some categories doubled for current or ex-smokers in contrast with never-smokers. This survey emphasises first, the continuing inadequacy of stop-smoking support even at specialist clinics, second, that patients who give up smoking are to be congratulated and benefit in the long-term but third, that the change in status can be recent and classification as ex-smoker can conceal high short-term risk, for which lipid profiles may also be significant and justify priority attention in management.

European Journal of Medical Research

The early cardiovascular toll of cigarette smoking in dyslipidaemic patients in the United Kingdom.

作者: Butowski P ; Winder A

Relationships between early cardiovascular risk at mean follow-up 1. 8 years and cigarette smoking status were investigated through analysis of data from participating clinics entered from 1981-1994 in the UK-Lipid Clinics Programme computerised database. Lipid profiles and new cardiovascular events were recorded for 3601 male, 4883 female human non-smokers mean age 44.7 and 53.1 years, 3077 male, 2275 female current smokers age 46.3 and 50.3 years and 7210 male, 4559 female age 49.2 and 53.3 years ever-smokers. Levels of triglycerides and total cholesterol increased across the gradient never/ex/current smoker, with a reverse gradient for HDL-cholesterol. Never-smokers were slightly lighter than other groups and males were younger, differences insufficient to explain the lipid variation. Minor differences in blood pressure between groups did not show this gradient and the development of new hypertension was not consistently related to smoking habits. In contrast the expression of newly-recorded cardiovascular disease was greater and in some categories doubled for current or ex-smokers in contrast with never-smokers. This survey emphasises first, the continuing inadequacy of stop-smoking support even at specialist clinics, second, that patients who give up smoking are to be congratulated and benefit in the long-term but third, that the change in status can be recent and classification as ex-smoker can conceal high short-term risk, for which lipid profiles may also be significant and justify priority attention in management.

100 项与 Anthra Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Anthra Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月26日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

5

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

戊柔比星 ( Top II )	卵巢癌更多	终止
AD-143 ( Top II )	肿瘤更多	终止
AD-312 ( Top II )	实体瘤更多	无进展
AD-288 ( PKC )	肺癌更多	无进展
AD-198 ( PKC x Top II )	肺癌更多	无进展